Nectar Lifesciences Limited

NSEI:NECLIFE 株式レポート

時価総額:₹9.2b

このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Nectar Lifesciences 過去の業績

過去 基準チェック /26

Nectar Lifesciencesの収益は年間平均-30.5%の割合で減少していますが、 Pharmaceuticals業界の収益は年間 増加しています。収益は年間17% 13.1%割合で 減少しています。 Nectar Lifesciencesの自己資本利益率は0.5%であり、純利益率は0.3%です。

主要情報

-20.7%

収益成長率

-20.7%

EPS成長率

Pharmaceuticals 業界の成長17.5%
収益成長率-11.4%
株主資本利益率0.6%
ネット・マージン0.4%
前回の決算情報30 Jun 2024

最近の業績更新

Recent updates

Nectar Lifesciences Limited (NSE:NECLIFE) Shares Fly 31% But Investors Aren't Buying For Growth

Aug 22
Nectar Lifesciences Limited (NSE:NECLIFE) Shares Fly 31% But Investors Aren't Buying For Growth

Here's Why Nectar Lifesciences (NSE:NECLIFE) Has A Meaningful Debt Burden

Jul 27
Here's Why Nectar Lifesciences (NSE:NECLIFE) Has A Meaningful Debt Burden

Nectar Lifesciences Limited (NSE:NECLIFE) Stock Catapults 27% Though Its Price And Business Still Lag The Industry

Feb 19
Nectar Lifesciences Limited (NSE:NECLIFE) Stock Catapults 27% Though Its Price And Business Still Lag The Industry

Does Nectar Lifesciences (NSE:NECLIFE) Have A Healthy Balance Sheet?

Dec 22
Does Nectar Lifesciences (NSE:NECLIFE) Have A Healthy Balance Sheet?

Nectar Lifesciences (NSE:NECLIFE) Has Debt But No Earnings; Should You Worry?

Jun 16
Nectar Lifesciences (NSE:NECLIFE) Has Debt But No Earnings; Should You Worry?

Nectar Lifesciences (NSE:NECLIFE) Takes On Some Risk With Its Use Of Debt

Jun 21
Nectar Lifesciences (NSE:NECLIFE) Takes On Some Risk With Its Use Of Debt

Nectar Lifesciences (NSE:NECLIFE) Takes On Some Risk With Its Use Of Debt

Jul 29
Nectar Lifesciences (NSE:NECLIFE) Takes On Some Risk With Its Use Of Debt

Is Nectar Lifesciences Limited (NSE:NECLIFE) A Risky Dividend Stock?

Feb 25
Is Nectar Lifesciences Limited (NSE:NECLIFE) A Risky Dividend Stock?

Nectar Lifesciences (NSE:NECLIFE) Has A Somewhat Strained Balance Sheet

Jan 21
Nectar Lifesciences (NSE:NECLIFE) Has A Somewhat Strained Balance Sheet

Zooming in on NSE:NECLIFE's 0.3% Dividend Yield

Nov 02
Zooming in on NSE:NECLIFE's 0.3% Dividend Yield

Does Nectar Lifesciences (NSE:NECLIFE) Have A Healthy Balance Sheet?

Sep 07
Does Nectar Lifesciences (NSE:NECLIFE) Have A Healthy Balance Sheet?

If You Had Bought Nectar Lifesciences (NSE:NECLIFE) Stock A Year Ago, You Could Pocket A 47% Gain Today

Aug 09
If You Had Bought Nectar Lifesciences (NSE:NECLIFE) Stock A Year Ago, You Could Pocket A 47% Gain Today

The Nectar Lifesciences (NSE:NECLIFE) Share Price Has Gained 47% And Shareholders Are Hoping For More

Aug 09
The Nectar Lifesciences (NSE:NECLIFE) Share Price Has Gained 47% And Shareholders Are Hoping For More

What You Can Learn From Nectar Lifesciences Limited's (NSE:NECLIFE) P/E

Jul 13
What You Can Learn From Nectar Lifesciences Limited's (NSE:NECLIFE) P/E

収支内訳

Nectar Lifesciences の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。


収益と収入の歴史

NSEI:NECLIFE 収益、費用、利益 ( )INR Millions
日付収益収益G+A経費研究開発費
30 Jun 2416,493619180
31 Mar 2416,846508660
31 Dec 2316,322818290
30 Sep 2315,241-288100
30 Jun 2315,148-2637970
31 Mar 2315,237-2427960
31 Dec 2216,120-1627890
30 Sep 2217,109287850
30 Jun 2216,8682727490
31 Mar 2216,6892507630
31 Dec 2115,421-2768570
30 Sep 2114,765-4548680
30 Jun 2115,387-5467420
31 Mar 2115,433-7338720
31 Dec 2017,586-2497650
30 Sep 2020,291-867760
30 Jun 2021,807128040
31 Mar 2023,6643188280
31 Dec 1925,9734198140
30 Sep 1926,8194468090
30 Jun 1928,2744807980
31 Mar 1927,8294768120
31 Mar 1818,7635237980
31 Mar 1716,4375538060
31 Mar 1616,7575428320
31 Mar 1516,4366636390
31 Mar 1416,3836219380

質の高い収益: NECLIFEは 高品質の収益 を持っています。

利益率の向上: NECLIFE過去に利益を上げました。


フリー・キャッシュフローと収益の比較


過去の収益成長分析

収益動向: NECLIFEの収益は過去 5 年間で年間30.5%減少しました。

成長の加速: NECLIFEは昨年収益を上げたため、収益成長率を 5 年間の平均と比較することは困難です。

収益対業界: NECLIFE昨年収益を上げたため、昨年の収益成長をPharmaceuticals業界 ( 18% ) と比較することは困難です。


株主資本利益率

高いROE: NECLIFEの 自己資本利益率 ( 0.5% ) は 低い とみなされます。


総資産利益率


使用総資本利益率


過去の好業績企業の発掘